The potential role of ivermectin (stromectol) in managing COVID-19 has been a subject of intense debate and scrutiny within the scientific community and among healthcare professionals. While some observational studies and small-scale trials have reported favorable outcomes with ivermectin treatment, others have raised concerns about methodological limitations and conflicting results. Regulatory agencies and professional medical organizations have emphasized the need for well-designed randomized controlled trials to evaluate the efficacy and safety of stromectol in COVID-19 patients.